Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

973
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
973
Angina IV: Management01:26

Angina IV: Management

493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

398
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.

American journal of preventive cardiology·2026
Same author

Capturing multi-disease states on a spectrum with machine learning and routine clinical data.

Med (New York, N.Y.)·2026
Same author

Remnant cholesterol - The transition from biomarker to risk factor.

Atherosclerosis·2026
Same author

Inclisiran in CKD: A Therapeutic Answer to a Persistent Treatment Gap.

Journal of the American Society of Nephrology : JASN·2026
Same author

Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults.

The Journal of clinical investigation·2026
Same author

Associations of 10-year predicted ASCVD risk by the PREVENT equations with AI-analyzed coronary atherosclerotic plaque characteristics.

American journal of preventive cardiology·2026

Related Experiment Video

Updated: Apr 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

An assessment by the Statin Muscle Safety Task Force: 2014 update.

Robert S Rosenson1, Steven K Baker2, Terry A Jacobson3

  • 1Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.

Journal of Clinical Lipidology
|May 6, 2014
PubMed
Summary

This expert panel reviewed statin-associated muscle adverse events, developing a clinical index for myalgia and guidance for patient evaluation. An algorithm was created to manage statin intolerance due to muscle issues.

Keywords:
Muscle adverse eventsMyalgiaMyopathyNeuromuscular testingRhabdomyolysisStatin intoleranceStatins

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Experiment Videos

Last Updated: Apr 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Statin medications are widely prescribed for lipid management.
  • Muscle-related adverse events are a concern with statin therapy.
  • Standardized definitions and evaluation methods for statin-induced myopathy are lacking.

Purpose of the Study:

  • To examine definitions of statin-associated muscle adverse events.
  • To develop a clinical index for assessing myalgia.
  • To provide guidance on diagnostic evaluations and management strategies for statin-associated muscle symptoms.

Main Methods:

  • Expert panel review of existing evidence.
  • Development of diagnostic criteria and clinical assessment tools.
  • Creation of a treatment algorithm for statin-intolerant patients.

Main Results:

  • Established clear definitions for statin-associated muscle adverse events.
  • Introduced a clinical index for evaluating myalgia.
  • Outlined indications for neuromuscular specialist referral and muscle biopsy.
  • Developed a practical algorithm for managing patients with statin-induced muscle symptoms.

Conclusions:

  • The panel provides a framework for consistent evaluation and management of statin-associated muscle adverse events.
  • This guidance aims to improve patient care and adherence to statin therapy.
  • The developed algorithm assists clinicians in diagnosing and treating muscle-related side effects.